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Independent predictors of breast malignancy in screen-detected
microcalcifications: biopsy results in 2545 cases
G Farshid*,1, T Sullivan2, P Downey1, PG Gill1 and S Pieterse1
1BreastScreen SA and SA Pathology, 1 Goodwood Road, Wayville, South Australia 5034, Australia; 2Data Management and Analysis Centre, Discipline
of Public Health, University of Adelaide, Adelaide, Australia
BACKGROUND: Mammographic microcalcifications are associated with many benign lesions, ductal carcinoma in situ (DCIS) and invasive
cancer. Careful assessment criteria are required to minimise benign biopsies while optimising cancer diagnosis. We wished to evaluate
the assessment outcomes of microcalcifications biopsied in the setting of population-based breast cancer screening.
METHODS: Between January 1992 and December 2007, cases biopsied in which microcalcifications were the only imaging abnormality
were included. Patient demographics, imaging features and final histology were subjected to statistical analysis to determine
independent predictors of malignancy.
RESULTS: In all, 2545 lesions, with a mean diameter of 21.8mm (s.d. 23.8mm) and observed in patients with a mean age of 57.7 years
(s.d. 8.4 years), were included. Using the grading system adopted by the RANZCR, the grade was 3 in 47.7%; 4 in 28.3% and 5 in
24.0%. After assessment, 1220 lesions (47.9%) were malignant (809 DCIS only, 411 DCIS with invasive cancer) and 1325 (52.1%)
were non-malignant, including 122 (4.8%) premalignant lesions (lobular carcinoma in situ, atypical lobular hyperplasia and atypical
ductal hyperplasia). Only 30.9% of the DCIS was of low grade.
Mammographic extent of microcalcifications 415mm, imaging grade, their pattern of distribution, presence of a palpable mass and
detection after the first screening episode showed significant univariate associations with malignancy. On multivariate modeling
imaging grade, mammographic extent of microcalcifications 415mm, palpable mass and screening episode were retained as
independent predictors of malignancy. Radiological grade had the largest effect with lesions of grade 4 and 5 being 2.2 and 3.3 times
more likely to be malignant, respectively, than grade 3 lesions.
CONCLUSION: The radiological grading scheme used throughout Australia and parts of Europe is validated as a useful system of
stratifying microcalcifications into groups with significantly different risks of malignancy. Biopsy assessment of appropriately selected
microcalcifications is an effective method of detecting invasive breast cancer and DCIS, particularly of non-low-grade subtypes.
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Microcalcifications are one of the main categories of abnormalities
detectable by mammograms. The widespread uptake of screening
mammography has been associated with a marked increase in the
diagnosis of ductal carcinoma in situ (DCIS), as this lesion is
frequently associated with dystrophic calcifications, particularly
when comedo necrosis is present. At present, DCIS constitutes one
in five screen-detected malignancies in our population-based
breast cancer-screening programme.
In addition to malignat lesions, many non-malignant processes also
produce dystrophic microcalcifications in breast tissue. In order to
minimise invasive investigations, radiologists take into account the
various characteristics of microcalcifications. The form, size,
pleomorphism and distribution of the calcifications provide clues to
the underlying pathology. Mammographic grading systems encapsulate
the overall level of concern. The grading system used throughout
Australia and parts of Europe is a five tier system that differs from
the BI-RADs system used in North America (National Breast
Cancer Centre, 2002). In this system, grade 3 lesions are regarded
as indeterminate/equivocal and lesions graded 3 and above require
imaging workup and possible biopsy.
In this study, we wished to review the outcomes of assessment of
microcalcifications detected through screening mammography at
our programme, with a particular interest in evaluating the
discriminating capacity of the mammographic grading system
used.
MATERIALS AND METHODS
The design of our breast cancer-screening programme
BreastScreen South Australia is part of a national breast cancer-
screening programme and has been accredited to provide this
service since 1991, after a pilot in 1989. The design of this
programme has been described previously (Farshid and Rush,
2004). In brief, asymptomatic women aged 50–69 years are invited
to participate at 1 or 2 yearly intervals, depending on family
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history. Two radiologists read two view screening mammograms
independently. A third reader arbitrates discordant results. All
imaging was based on film screen mammography for the study
period. A 5-tier grading scheme is applied (National Breast Cancer
Centre, 2002), grade 1, normal; grade 2, benign; grade 3,
indeterminate/equivocal, grade 4, suspicious for malignancy and
grade 5, radiologically malignant. Women with grade 1 or 2 lesions
are cleared and are invited to return for re-screening in 1–2 years.
The remaining lesions are recalled for further assessment. Based
on workup mammography and, in most cases, ultrasound
examination, the lesion is re-graded. Some lesions are cleared as
a result of these additional imaging tests. Needle biopsy is
performed for those that have imaging grades 3 and above.
Lesions with malignant needle biopsy findings are referred for
treatment. Diagnostic open biopsy is used when the imaging and
needle biopsy findings are discordant or indefinite. For lesions
undergoing surgery, all final pathology reports and treatment data
are audited and are entered prospectively into an electronic
database. Follow-up of clients who were not referred for surgery is
through tracking them during subsequent screening visits and also
via the State Cancer Registry, which is required to notify screening
programmes of any cancers diagnosed in their clients within 27
months of a negative screen (interval cancers; BreastScreenAus-
tralia, 2005). Treating surgeons and general practitioners also
notify us of any interval cancers.
Study design
We searched our prospectively accrued electronic archives for
lesions screened during the period January 1992 to December 2007,
in which the dominant radiological abnormality was coded as
microcalcifications. We restricted inclusion to those cases in which
the only imaging abnormality was microcalcifications, without
other associated abnormalities, such as a mass on mammography
or ultrasound. To simplify analysis, cases with more than one
mammographic lesion are excluded. For each lesion, we tabulated
patient demographics, imaging grade, mammographic extent,
pattern of distribution of microcalcifications, biopsy methods
and final outcome.
For lesions that were not excised, we obtained follow-up
information by tracking the clients in our own database during
their subsequent screening visits and through notifications of
breast cancer diagnoses from the State Cancer Registry.
Radiological characteristics
In our programme, in accordance with the criteria set by the Royal
Australian and New Zealand College of Radiologists (National
Breast Cancer Centre, 2002), we designate microcalcifications as
grade 5 if they exhibit typical malignant features of distribution
and morphology:
(i) Distribution - clustered or,
- aligned (separated calcifications contained
within a duct).
(ii) Morphology - intraluminal (elongated calcifications with or
without branching).
- granular (significant variability in size and
shape).
Grade 4 calcifications exhibit significant pleomorphism but do not
have clear-cut malignant features. Grade 3 calcifications do not
exhibit classical benign features and are mildly pleomorphic. Figures
1–3 illustrate typical cases of grade 3–5 microcalcifications.
Statistical analyses were performed using SAS version 9.2
software (SAS Institute Inc., Cary, NC, USA). Risk factors
satisfying a P-value criterion of Po0.20 in univariate log binomial
regression models were included into a multivariate log binomial
regression model. A P-value o0.05 in the multivariate model was
considered statistically significant.
Consent
This study was conducted with institutional review board
approval; informed consent was waived.
Figure 1 Screening mammogram showing high-grade (grade 5)
microcalcifications. (A) Cranio-caudal and (B) lateral views. Note: Linear
calcifications of casting morphology.
Figure 2 Grade 4 microcalcifications. A new lesion in the current round.
Although the microcalcifications have somewhat smooth margins, they
have a linear configuration with possible branching forms. The findings were
regarded as suspicious for DCIS. This was confirmed by core biopsy.
Figure 3 Indeterminate (category 3) microcalcifications. A small cluster
of slightly pleomorphic microcalcifications.
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Between January 1992 and December 2007, 2545 cases of screen-
detected microcalcifications of at least grade 3 were assessed by
biopsy (mean 153.4 lesions per year). The mean age of the patients
was 57.7 years (s.d. 8.4 years, range 40–86 years). In 187 women
(7.3%), there was a very strong family history of breast cancer,
defined in our programme historically as having either a first-
degree relative with breast cancer before the age of 50 years, or
with bilateral breast cancers at any age, or two first-degree relatives
with breast cancer at any age. The microcalcifications were in the
left breast in 1118 (53.0%) and in the right side in 990 cases
(47.0%). Though no imaging features of invasion were identified, a
mass was palpable in the region of the mammographic abnorm-
ality in 137 cases (5.4%). The calcifications were detected in the
first episode of screening (round 1) in 894 lesions (35.1%) and
during the subsequent 2–15 rounds in the remaining 64.9%.
Imaging features
The lesions were classified as grade 3 in 1215 lesions (47.7%),
grade 4 in 719 lesions (28.3%) and grade 5 in 611 lesions (24.0%).
The distribution of the calcifications is specified in 2086 cases. The
microcalcifications formed a single cluster in 1357 cases (65.1%),
multiple clusters in 224 cases (10.7%) and were scattered in 505
cases (24.2%). The mammographic extent of microcalcifications
was specified in 2088 cases. This ranged from 2 to 430mm with a
mean value of 21.8mm (s.d. 23.8mm). In total, 1229 (58.9%)
microcalcifications were p15mm and 859 (41.1%) were 415mm
in imaging extent.
Final outcome
After a diagnostic workup, 1220 lesions (47.9%) were found to be
malignant and 1325 (52.1%) non-malignant. This group includes
122 (4.8%) premalignant lesions, comprising lobular carcinoma
in situ, atypical lobular hyperplasia and atypical ductal hyperplasia
(ADH). The malignant lesions consisted of 809 cases of DCIS
(31.8%) and 411 invasive cancers (16.1%), almost all associated
with a component of DCIS.
The histological grade of the DCIS is available in 677 of the 809
cases. The DCIS was classified as high grade in 396 cases (58.5%),
intermediate grade in 64 cases (9.5%), low grade in 209 cases
(30.9%) and as other, special subtypes (e.g., papillary, spindle cell)
in 8 cases (1.2%).
Among malignant lesion, high-grade DCIS was observed in
88.5% of radiological grade 3 lesions, 90.8% of grade 4 lesions and
87.2% of grade 5 lesions. These differences were not significant
(P¼ 0.23).
The histological extent of the DCIS was specified in 620 cases.
The DCIS measured 1–15mm in 236 cases (38.1%), 16–40mm
in 263 cases (42.4%) and larger than 40mm in 121 cases (19.5%).
Of the invasive cancers, 87 (21.2%) were grade 1, 180 (43.8%)
were grade 2, 58 (14.1%) were grade 3, whereas in 77 (18.7%)
histological grade could not be assessed formally mostly due to
small size. Information regarding grade was not provided in nine
cases (2.2%). Among the 359 invasive cancers with available data,
69 (19.2%) were 1–2mm in diameter on histology, 76 (21.2%) were
3–5mm, 101 (28.1%) were 6–10mm, 59 (16.4%) were 11–15mm,
28 (7.8%) were 16–20mm, 24 (6.7%) were 21–50mm (T2) and
2 cancers (0.6%) were 450mm (T3).
Information regarding axillary staging is available in 352 of 411
invasive cancers. Nodal metastases were detected in 55 cases
(15.6%). Of these cases, 25 had only one positive node, 22 had two to
four positive nodes and 8 cases had more than four positive nodes.
Cancers diagnosed subsequently
Eleven other women have developed breast malignancies, 2 DCIS, 9
invasive cancers, after non-malignant biopsies. Upon review, 7 of the
11 cases had benign assessment results for the microcalcifications,
but later developed true interval cancers, affecting the ipsialteral
breast in 4 cases and the contralateral breast in the other 3 cases.
The details of the remaining four cases are as follows: in two
women, core biopsies of the microcalcifications led to a diagnosis
of ADH. These women were subsequently diagnosed with DCIS.
One was recalled early and the diagnosis was made at the
subsequent screen 1 year later. The second woman declined further
invitations for screening. Her DCIS was diagnosed 7.6 years later.
Current assessment protocols would have recommended immedi-
ate diagnostic open biopsy in both these women.
The third woman had grade 3 microcalcifications, assessed at
the time by FNA biopsy and interpreted as showing benign
changes. She was later diagnosed with invasive cancer. On review,
this is classified as a missed interval cancer. Under current
protocols she would be assessed by vacuum-assisted core biopsy
rather than by FNA.
The fourth woman had two clusters of microcalcifications at
screening. After a non-diagnostic cytology result, she proceeded to
open biopsy. This was directed at one cluster of microcalcifications
and the histology of that lesion was benign. The other cluster was not
excised. It was later found to include an invasive cancer. Current
protocols would require vacuum-assisted core biopsy of this case.
Predictors of malignancy – univariate analysis
Table 1 shows the proportion of malignancy for the variables of
interest, and Table 2 outlines the univariate analysis of these
findings. Women with a strong family history of breast cancer had
a malignant lesion in 101 of 187 cases (54.0%), compared with










Strong family history of
breast cancer
No 2358 1119 47.5
Yes 187 101 54.0
Age group (years) o50 360 150 41.7
50–59 1180 567 48.1
60–69 789 381 48.3
70+ 216 122 56.5
Screening round 1 894 363 40.6
2–5 1290 674 52.3
6+ 361 183 50.7
Palpable mass No 2408 1100 45.7
Yes 137 120 87.6
Radiological grade 3 1215 289 23.8
4 719 373 51.9
5 611 558 91.3
Distribution of
calcifications







Dispersed 505 303 60.0
Imaging extent Missing 457 255 55.8
15 or less 1229 424 34.5
415 859 541 63.0
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47.5% (1119 of 2358) of women without such a history. The relative
risk (RR) was 1.1, not reaching statistical significance (0.068).
The proportion of lesions found to be malignant varied with age,
being 41.7% in 40–49 year olds, 48.1% for women in their 50’s,
48.3% for those in their 60’s and 56.5% for those X70 years. The
RRs between the different age groups varied between 1 and 1.36,
the differences being significant, as shown in Table 2. The biggest
difference was a RR of 1.36 between womenX70 years and women
younger than 50. The differences between women in their 50’s vs
women in their 60’s, the target age group for our programme, were
not significant (RR¼ 1.0).
Among lesions detected in the first episode of screening 40.6%
(363 of 894) proved to be malignant, whereas 51.9% (857 of 1651)
of microcalcifications assessed in subsequent screening rounds
were malignant. Compared with lesions detected at the first screen,
the RR for detection at screening rounds 2–5 was elevated
significantly at 1.29, and was 1.25 for lesions detected in rounds 6
or later. The rates of malignancy were, however, not significantly
different for lesions assessed in rounds 2–5 vs later rounds.
Among the 137 women with a significant palpable mass
corresponding to the mammographic lesion, 120 (87.6%) proved
to have a malignancy compared with 45.7% of other women.
Lesions associated with a palpable mass had a significantly higher
RR for malignancy at 1.9 (Po0.0001). The majority of the lesions
with a palpable mass (70.8%) had highly suspicious imaging
features (grade 5). Lesions with grade 5 imaging features and a
palpable mass proved to be malignant in 99.0% of cases.
The likelihood of malignancy varied significantly with the
radiological grade of the calcifications. Among grade 3 lesions, 289
of 1215 (23.8%) were malignant, the corresponding figures were
373 of 719 (51.9%) for grade 4 lesions and 558 of 611 (91.3%) for
grade 5 lesions. Compared with grade 3 lesions, the RRs for
malignancy were 2.18 for grade 4 lesions and 3.84 for grade 5
lesions. These differences were significant, as was the difference
between grade 4 and grade 5 lesions with the RR¼ 1.78
(Po0.0001).
The rate of malignancy was 40.0% (543 of 1357) for cases with a
single cluster of microcalcifications, 50% (112 of 224) for those
with multiple clusters and 60.0% (303 of 505) for those with
dispersed microcalcifications. Compared with women who had
only one cluster of microcalcifications, the RR of malignancy for
women with multiple clusters was significantly raised at 1.25. The
RR was 1.5 for women with dispersed microcalcifications. The RR
of malignancy was significantly higher at 1.20 for women with
dispersed calcifications compared with those with multiple clusters
of microcalcifications.
The likelihood of malignancy increased with the extent of the
lesion on imaging. The rate of malignancy was 26.9% for lesions
under 10mm, 44.4% for those 10–19mm, 59.2% for lesions
20–29mm, 65.3% for lesions 30–39mm, 68.3% for lesions
40–49mm and 65.4% for lesions larger than 50mm. An analysis
of the log of probability of malignancy and mammographic extent
of microcalcifications showed a step-wise increase after 15mm and
after 40mm (Figure 4). Using these cut offs, the rate of malignancy
was 424 of 1229 (34.5%) for lesions p15mm on imaging, 360 of
588 (61.2%) for lesions 16–40mm and 181 of 271 (66.8%) for
lesions 440mm. Compared with microcalcifications p15mm in
extent, the RR of malignancy was 1.8 for larger lesions. The
differences were significant Po0.01.
Multivariate analysis
The results of the multivariate analysis are shown in Table 3. The
following factors were retained as independent predictors of
malignancy: radiological grade, episode of screening, mammo-
graphic extent of microcalcifications and association with a
palpable mass. Strong family history for breast cancer, age group
and the distribution of calcifications lost significance in the
multivariate analysis.
In the multivariate model, radiological grade had the largest effect.
Compared with grade 3 lesions, grade 4 microcalcifications had a
2.2-fold higher RR, whereas the RR for grade 5 lesions was 3.3. The
RR of grade 5 vs grade 4 microcalcifications was 1.5, also significant.
Compared with women whose microcalcifications were detected
at the first screening episode, those detected in the subsequent
2–5 rounds had a higher likelihood of malignancy with a RR of 1.4.
The RR was slightly higher at 1.5 for microcalcifications detected








Strong family history: yes vs no 1.14 0.99 1.31 0.07
Age group (years) 0.01
50–59 vs o50 1.15 1.01 1.32 0.04
60–69 vs o50 1.16 1.01 1.34 0.04
70+ vs o50 1.36 1.14 1.61 o0.01
60–69 vs 50–59 1.01 0.92 1.10 0.92
70+ vs 50–59 1.18 1.03 1.34 0.02
70+ vs 60–69 1.17 1.02 1.34 0.03
Screening round o0.01
2–5 vs 1 1.29 1.17 1.41 o0.01
6+ vs 1 1.25 1.10 1.42 0.00
6+ vs 2–5 0.97 0.87 1.09 0.60
Palpable mass: yes vs no 1.92 1.78 2.07 o0.01
Radiological grade o0.01
4 vs 3 2.18 1.93 2.47 o0.01
5 vs 3 3.84 3.46 4.26 o0.01
5 vs 4 1.76 1.63 1.90 o0.01
Distribution o0.01
Multiple vs single 1.25 1.08 1.45 o0.01
Dispersed vs single 1.50 1.36 1.65 o0.01
Dispersed vs multiple 1.20 1.03 1.39 0.02
Size 415 vs 15 or less 1.83 1.66 2.00 o0.01
Abbreviations: CI¼ confidence interval; DCIS¼ ductal carcinoma in situ. In order to
identify risk factors for malignancy (DCIS or invasive), univariate log binomial
regression models were fitted to the data. Relative risks and 95% CIs for each of the




























































Figure 4 Scatter plot of log probability of malignancy (y axis) vs
mammographic extent of microcalcifications. Because the relationship
between size and log of the probability of malignancy is not linear, the
appropriate statistical analysis was for size to be categorised asp15mm or
415mm rather than as a continuous variable.
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in rounds 6 and later but this difference did not reach statistical
significance.
The extent of the microcalcifications was another independent
predictor of malignancy. Compared with lesions p15mm, those
415mm were 1.3 times more likely to be malignant (Po0.0001).
The presence of a palpable mass associated with the mammo-
graphic abnormality, although found in only 5.3% of patients,
increased the RR to 1.1, which was significant (P¼ 0.01).
DISCUSSION
In this large series of 2545 microcalcifications biopsied in the setting
of an accredited population-based breast cancer-screening pro-
gramme, 47.9% of the lesions biopsied were malignant, of which
one-third were invasive cancers. This series has focused on cases in
which the only mammographic abnormality was microcalcifica-
tions, without associated masses. Radiological grade was the most
important independent predictor of malignancy, followed by dete-
ction after the first episode of screening, mammographic extent of
microcalcifications and association with a clinically palpable mass.
The strengths and limitations of radiological grading for
microcalcifications
This analysis establishes the discriminative value of the radio-
logical grading scheme adopted by the RANZCR in stratifying
microcalcifications into risk groups with significantly different
likelihoods of malignancy. This grading system has been in use at
our centre for the last 23 years and is used throughout Australia,
New Zealand and part of Europe. The positive predictive value
(PPV) was 23.8% for grade 3 lesions, 54.5% for grade 4 lesions and
92.1% of grade 5 lesions (P¼ 0.0001) with corresponding RRs
of 2.2 for grade 4 lesions and 3.3 for grade 5 lesions when grade
3 lesions are the frame of reference.
The risk stratification by radiological grade is clinically helpful
in counselling women. In particular, the high PPV of category 5
radiology, signifies a greater than 90% chance of malignancy,
mandating careful exclusion of malignancy. However, even among
grade 5 lesions, almost 10% of cases were ultimately shown to be
non-malignant histologically. This observation reiterates the
necessity to evaluate all suspicious microcalcifications by tissue
biopsy before definitive treatment, as imaging alone is not a
sufficiently robust determinant of malignancy.
The PPVs of the different lesion grades in this system are
different and generally higher than the corresponding figures
reported using the BIRAD system, underscoring the lack of
equivalence of the two systems. Recent studies indicate a broad
range of experiences in the PPV for the BIRAD 4 and 5 categories,
reporting a range of 17–53% for BIRAD category 4 and 44–91%
for category 5 lesions (Gulsun et al, 2003; Lazarus et al, 2006; Bent
et al, 2010). The higher end of this range is similar to the 92.1%
PPV of a grade 5 classification in our system.
Although the radiological grade successfully stratified micro-
calcifications into groups with different risks of malignancy, the
radiological grade had no bearing on the histological grade of the
underlying DCIS. Thus, regardless of the radiological grade,
between 87 and 91% of DCIS found as a result of assessing
screen-detected microcalcifications were found to show comedo
necrosis. It is the necrotic contents of the involved ducts that
undergo dystrophic calcification, and the presence of extensive
comedo necrosis excludes a diagnosis of low-grade DCIS
(Silverstein and Buchanan, 2003), explaining the over-representa-
tion of higher grades of DCIS in this setting. Our observations are
consistent with other reports confirming that radiological grade
does not predict DCIS grade reliably (Hermann et al, 1999; Dinkel
et al, 2000; Slanetz et al, 2001; Stomper et al, 2003).
The tradeoff between high cancer detection and the
morbidity of a high recall rate
Although microcalcifications represent an early sign of an under-
lying breast malignancy, in the setting of population screening, the
aim of cancer detection has to be balanced against the morbidity
associated with investigation of non-malignant processes. As
microcalcifications are a common finding on screening mammo-
grams, stringent selection criteria and reasonable thresholds for
recall are required to limit unnecessary investigations of large
numbers of women.
Nationally organised population-based breast cancer-screening
programmes, such as those implemented in Europe and Australia,
have set accreditation standards to mitigate the unintended harms
associated with screening of asymptomatic women and to reduce
the rate of invasive investigations and anxiety for the participants.
In our programme, the proportion of women recalled for
assessment after their first round of screening should be o10%;
and o5% for those returning in subsequent rounds (BreastScree-
nAustralia, 2005). This audit of over 2500 microcalcifications
assessed at our centre demonstrates that 47.9% of the biopsy cases
proved to be malignant, whereas premalignant lesions were found
in a further 4.8% of the women. This is a higher rate of malignancy
than reported by some investigators, where the rate of malignancy
for microcalcifications has been in the region of 25–30%
(Kuzmiak et al, 2006; Lazarus et al, 2006; Burnside et al, 2007;
Bent et al, 2010). Our findings are similar to the experience of the
Nottingham group, who used a similar design and radiological
grading scheme and found a 45% rate of malignancy (Burrell et al,
1996). In addressing the variation in the reported rates of
malignancy, we note that the present series has focused
on microcalcifications that were biopsied. Microcalcifications
recalled, but cleared after further imaging workup, are not
included. Their inclusion would have reduced the rate of
malignancy significantly. A wider audit to include all cases is
of interest and is planned for the future, but is outside the scope of
the present series.
Table 3 Multivariate model for malignancy. A multivariate log binomial








Strong family history: yes vs no 1.12 0.99 1.28 0.08
Age group (years) 0.14
50–59 vs o50 1.03 0.89 1.18 0.72
60–69 vs o50 0.96 0.82 1.11 0.58
70+ vs o50 1.11 0.93 1.32 0.24
60–69 vs 50–59 0.93 0.85 1.02 0.14
70+ vs 50–59 1.08 0.95 1.22 0.23
70+ vs 60–69 1.16 1.02 1.32 0.03
Screening round o0.01
2–5 vs 1 1.42 1.27 1.58 o0.01
6+ vs 1 1.54 1.35 1.77 o0.01
6+ vs 2–5 1.09 0.98 1.21 0.11
Palpable mass: yes vs no 1.13 1.03 1.24 0.01
Radiological grade o0.01
4 vs 3 2.20 1.94 2.51 o0.01
5 vs 3 3.26 2.90 3.65 o0.01
5 vs 4 1.48 1.36 1.61 o0.01
Distribution 0.52
Multiple vs single 0.96 0.84 1.10 0.57
Dispersed vs single 1.03 0.94 1.13 0.51
Dispersed vs multiple 1.07 0.95 1.22 0.28
Size 415 vs 15 or less 1.29 1.17 1.44 o0.01
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Importance of microcalcifications in the diagnosis of
early-stage breast cancer
The detection of small cancers, defined as thosep15mm in diameter
on histology, is an important indicator of screening quality. Our
national accreditation standards mandate that at least 25 screen-
detected cancers per 100 000 women screened should be p15mm
(BreastScreenAustralia, 2005). Our data demonstrate that in
addition to the strong association with high grade DCIS, the
assessment of screen-detected microcalcifications is an important
method of detecting invasive cancers, including small invasive
cancers. In this series, 32.6% (235 of 721) of malignant cases,
representing 16.1% of the entire cohort of lesions biopsied,
constituted invasive cancers. This is despite the fact that our
inclusion criteria limited the study to cases where the radiological
abnormality was classified as only microcalcifications, without
other associated imaging abnormalities. As detailed earlier, 85%
(181 of 213) of the invasive cancers were under 16mm in diameter.
Despite their small size, only 21.2% of these cancers were grade 1,
and 15.6% of them had metastasised to lymph nodes. The
significant association of grade 3 cancers with DCIS was
documented by Chagpar et al (2009) and evidence has been
presented that when invasive malignancies present as calcifica-
tions, the invasive cancers are often HER2 positive, a feature that
has been associated with poorer prognosis in prior studies (Gajdos
et al, 2002; Seo et al, 2006).
Molecular studies of precursor lesions of breast cancer show a
dichotomous pattern, grouping low-grade DCIS with low-grade
invasive cancers, separate from the pairing of higher grade DCIS
with grade 3 invasive cancers along a different pathway (Simpson
et al, 2005). It appears that the assessment of screen-detected
microcalcifications permits preferential diagnosis of higher grades
of DCIS and of biologically more aggressive subsets of invasive
cancer with which they are associated. In this context, the
assessment of mammographic microcalcifications represents a
valuable opportunity for altering the natural history of these
cancers and reducing mortality from breast cancer.
Concerns of over diagnosis
One of the criticisms of breast cancer-screening programmes is
that a proportion of cancers detected through screening mammo-
graphy may have been indolent and may never have presented
clinically during the woman’s lifetime, had they not been detected
by screening. To the extent that these women face the morbidity
and anxiety associated with the diagnosis and treatment of breast
cancer, the diagnosis of these cancers is regarded as one of the
negative consequences of screening. As there are presently no
reliable means of predicting at the individual level which cancers
are destined to progress and which will remain indolent, the
estimates of the magnitude of such over-diagnosis are based on
statistical inferences, with a rather wide range of estimates
spanning zero to over 30% of cancers (National Breast Ovarian
Cancer Centre, 2010). Nevertheless, the diagnosis of DCIS is
included in these calculations and accounts for much of the
allegedly over-diagnosed malignancies. We note that it has been
established that DCIS shares the same predisposing factors as
invasive breast cancer (Longnecker et al, 1996; Kerlikowske et al,
1997, 2003; Trentham-Dietz et al, 2000; Wohlfahrt et al, 2004) and
that women with a diagnosis of DCIS are at 10 times greater risk
for the future development of invasive breast cancer (Betsill et al,
1978; Page et al, 1995; Ernster et al, 2002). Recent trials, conducted
in the era of screen-detected DCIS, have demonstrated that within
4–5 years after treatment of DCIS by local excision alone, women
had an 8% rate of developing invasive breast cancer in the same
region of the breast. These invasive cancers were more likely to be
high grade than low grade (Kerlikowske et al, 2003). Treatment of
the DCIS by the addition of radiation therapy or Tamoxifen halved
the risk of development of invasive cancer (Fisher et al, 1999;
Houghton et al, 2003). The relatively rapid time frame for the
development of invasive cancer suggests that screen-detected DCIS
is not a trivial process, but a non-obligate precursor of invasive
breast cancer, and as such represents an important opportunity for
medical intervention. Indirect support for this view has emerged
from recent biological research, elucidating common defects in the
molecular genetics of in situ and invasive breast cancers (Stratton
et al, 1995; Castro et al, 2008; Wiechmann and Kuerer, 2008).
Rather than upholding the validity of concerns for over-diagnosis
of an indolent process, our findings support the view that the
assessment of microcalcifications leads to the detection of a
significant number of biologically significant invasive cancers and
preferentially detects higher grades of DCIS (Franceschi et al, 1990;
Evans and Blanks, 2002; Stomper et al, 2003; Kuzmiak et al, 2006).
We found mammographic extent of microcalcifications to be an
independent predictor of malignancy. The analysis of the relation-
ship between the mammographic extent of microcalcifications and
malignancy revealed an apparent stepwise increase in the likelihood
of malignancy, with the increases occurring in the regions of 15 and
40mm. We note that these are the cut offs used in the Van Nuys
Prognostic index, but in that setting applied to the histological as
opposed to the imaging extent of the lesion (Silverstein and Lagios,
2010). Even among lesions o10mm in extent 16.9% proved to be
malignant, emphasising the need for vigilance.
Our results highlight the value of physical examination.
Although a palpable mass was associated with the imaging
abnormality in only a minority of the women, this finding was
highly predictive of a malignant diagnosis. This association has
implications for the design of screening programmes, as inclusion
of physical examination in the assessment process provides an
additional safety net in avoiding false negative assessment results.
The observed significant difference in the rate of malignancy
when the microcalcifications were detected after the first episode of
screening is likely due to the fact that recall in subsequent rounds
signifies interval change, either through the new development of
microcalcifications or significant interval progression between
screening mammograms. This observation is accounted for by the
fact that the women are older in subsequent rounds, and age is a
risk factor for the development of malignancy. But also, since in
subsequent rounds the radiologists have access to the prior images
taken at preceding rounds, they are in a better position to detect
true interval changes. Consequently stable microcalcifications, likely
to be benign, are apt not to be recalled for assessment.
Among the factors that were not retained in the final model, the
findings in relation to age were of interest. The rate of malignancy
among the women younger than the target age group of 50–69
years was 41.7%. This was a significantly lower rate than the
48.05% within the target age group. Women older than 70 years
had the highest rate of malignant diagnoses at 56.5%. Although age
was not an independent predictor of malignancy when other
variables were included, these observations may be of interest in
the ongoing debate regarding the optimal age limits for screening.
Family history was reported in relatively few women, and while
women with a strong family history had a RR of 1.14, this effect
was not significant in the univariate or indeed the final multi-
variate model. These findings may contribute to the discussions
regarding the frequency of screening, particularly for women with
a family history of breast cancer.
CONCLUSIONS
The assessment of screen-detected microcalcifications represents
an important opportunity to diagnose DCIS and biologically
significant invasive breast cancer at an early stage. Although the
thresholds for recall and biopsy of microcalcifications may vary
between centres, at our institution almost half of lesions biopsied
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proved to be malignant. This audit demonstrates a relatively high
specificity of biopsy assessment, ensuring that the morbidity
associated with unnecessary biopsy is reduced, while achieving
high cancer detection rates.
The demonstration of the stepwise increase in the likelihood of
malignancy between lesions of different imaging grade and the
significant differences between these grades validates the grading
scheme adopted by the Royal Australian and New Zealand College
of Radiologists.
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